Manager × security

ORBIMED ADVISORS LLC JANX holdings history

Who else holds this security? →

JANUX THERAPEUTICS INC · CUSIP 47103J105 · CIK 1055951

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, ORBIMED ADVISORS LLC reported 524.70K JANX (shares), valued at $8.06M, or 0.15% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
0.15%
Shares
524.70K
524,700
Reported value
$8.06M
USD

Shares decreased 46.66%; reported value decreased 41.05%, and weight changed -0.15 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.15%524,700SEC filing ↗Filed Aug 14, 2026
Q1 20260.30%983,600SEC filing ↗Filed May 15, 2026
Q4 20250.55%1,954,426SEC filing ↗Filed Feb 17, 2026
Q3 20251.04%1,766,100SEC filing ↗Filed Nov 14, 2025
Q2 20250.71%1,210,300SEC filing ↗Filed Aug 14, 2025
Q1 20250.49%758,566SEC filing ↗Filed May 15, 2025
Q4 20240.85%758,566SEC filing ↗Filed Feb 14, 2025
Q3 20241.05%1,258,566SEC filing ↗Filed Nov 14, 2024
Q2 20242.50%2,979,828SEC filing ↗Filed Aug 14, 2024
Q1 20242.97%4,275,553SEC filing ↗Filed May 15, 2024
Q4 20230.72%3,317,927SEC filing ↗Filed Feb 14, 2024
Q3 20230.72%3,317,927SEC filing ↗Filed Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20230.72%3,317,927$33.44MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 20230.72%3,317,927$35.60MShares unchanged; reported value increased 6.45%, and weight changed +0.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 20242.97%4,275,553$160.97MShares increased 28.86%; reported value increased 352.16%, and weight changed +2.25 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20242.50%2,979,828$124.82MShares decreased 30.31%; reported value decreased 22.46%, and weight changed -0.47 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20241.05%1,258,566$57.18MShares decreased 57.76%; reported value decreased 54.19%, and weight changed -1.45 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20240.85%758,566$40.61MShares decreased 39.73%; reported value decreased 28.97%, and weight changed -0.20 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20250.49%758,566$20.48MShares unchanged; reported value decreased 49.57%, and weight changed -0.36 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20250.71%1,210,300$27.96MShares increased 59.55%; reported value increased 36.50%, and weight changed +0.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20251.04%1,766,100$43.16MShares increased 45.92%; reported value increased 54.39%, and weight changed +0.33 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20250.55%1,954,426$26.97MShares increased 10.66%; reported value decreased 37.51%, and weight changed -0.49 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20260.30%983,600$13.67MShares decreased 49.67%; reported value decreased 49.31%, and weight changed -0.25 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20260.15%524,700$8.06MShares decreased 46.66%; reported value decreased 41.05%, and weight changed -0.15 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
ORBIMED ADVISORS LLC · JANUX THERAPEUTICS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1055951","quarter":"2026Q2","cusip":"47103J105"}

get_institutional_manager_history
{"cik":"1055951","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.